1
|
Saadh MJ, Abdulsahib WK, Mustafa AN, Zabibah RS, Adhab ZH, Rakhimov N, Alsaikhan F. Recent advances in natural nanoclay for diagnosis and therapy of cancer: A review. Colloids Surf B Biointerfaces 2024; 235:113768. [PMID: 38325142 DOI: 10.1016/j.colsurfb.2024.113768] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2023] [Revised: 01/04/2024] [Accepted: 01/23/2024] [Indexed: 02/09/2024]
Abstract
Cancer is still one of the deadliest diseases, and diagnosing and treating it effectively remains difficult. As a result, advancements in earlier detection and better therapies are urgently needed. Conventional chemotherapy induces chemoresistance, has non-specific toxicity, and has a meager efficacy. Natural materials like nanosized clay mineral formations of various shapes (platy, tubular, spherical, and fibrous) with tunable physicochemical, morphological, and structural features serve as potential templates for these. As multifunctional biocompatible nanocarriers with numerous applications in cancer research, diagnosis, and therapy, their submicron size, individual morphology, high specific surface area, enhanced adsorption ability, cation exchange capacity, and multilayered organization of 0.7-1 nm thick single sheets have attracted significant interest. Kaolinite, halloysite, montmorillonite, laponite, bentonite, sepiolite, palygorskite, and allophane are the most typical nanoclay minerals explored for cancer. These multilayered minerals can function as nanocarriers to effectively carry a variety of anticancer medications to the tumor site and improve their stability, dispersibility, sustained release, and transport. Proteins and DNA/RNA can be transported using nanoclays with positive and negative surfaces. The platform for phototherapeutic agents can be nanoclays. Clays with bio-functionality have been developed using various surface engineering techniques, which could help treat cancer. The promise of nanoclays as distinctive crystalline materials with applications in cancer research, diagnostics, and therapy are examined in this review.
Collapse
Affiliation(s)
- Mohamed J Saadh
- Faculty of Pharmacy, Middle East University, Amman 11831, Jordan
| | - Waleed K Abdulsahib
- Department of Pharmacology and Toxicology, College of Pharmacy, Al Farahidi University, Baghdad, Iraq
| | | | - Rahman S Zabibah
- Medical Laboratory Technology Department, College of Medical Technology, The Islamic University, Najaf, Iraq
| | | | - Nodir Rakhimov
- Department of Oncology, Samarkand State Medical University, Amir Temur street 18, Samarkand, Uzbekistan
| | - Fahad Alsaikhan
- College of Pharmacy, Prince Sattam Bin Abdulaziz University, Alkharj, Saudi Arabia; School of Pharmacy, Ibn Sina National College for Medical Studies, Jeddah, Saudi Arabia.
| |
Collapse
|
2
|
Chaurasia M, Singh R, Sur S, Flora SJS. A review of FDA approved drugs and their formulations for the treatment of breast cancer. Front Pharmacol 2023; 14:1184472. [PMID: 37576816 PMCID: PMC10416257 DOI: 10.3389/fphar.2023.1184472] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2023] [Accepted: 06/23/2023] [Indexed: 08/15/2023] Open
Abstract
Breast cancer is one of the most diagnosed solid cancers globally. Extensive research has been going on for decades to meet the challenges of treating solid tumors with selective compounds. This article aims to summarize the therapeutic agents which are either being used or are currently under approval for use in the treatment or mitigation of breast cancer by the US FDA, to date. A structured search of bibliographic databases for previously published peer-reviewed research papers on registered molecules was explored and data was sorted in terms of various categories of drugs used in first line/adjuvant therapy for different stages of breast cancer. We included more than 300 peer-reviewed papers, including both research and reviews articles, in order to provide readers an useful comprehensive information. A list of 39 drugs are discussed along with their current status, dose protocols, mechanism of action, pharmacokinetics, possible side effects, and marketed formulations. Another interesting aspect of the article included focusing on novel formulations of these drugs which are currently in clinical trials or in the process of approval. This exhaustive review thus shall be a one-stop solution for researchers who are working in the areas of formulation development for these drugs.
Collapse
Affiliation(s)
| | | | | | - S. J. S. Flora
- Era College of Pharmacy, Era University, Lucknow, Uttar Pradesh, India
| |
Collapse
|
3
|
Rizwanullah M, Perwez A, Alam M, Ahmad S, Mir SR, Rizvi MMA, Amin S. Polymer-lipid hybrid nanoparticles of exemestane for improved oral bioavailability and anti-tumor efficacy: An extensive preclinical investigation. Int J Pharm 2023; 642:123136. [PMID: 37311498 DOI: 10.1016/j.ijpharm.2023.123136] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2023] [Revised: 05/29/2023] [Accepted: 06/09/2023] [Indexed: 06/15/2023]
Abstract
Exemestane (EXE), an irreversible aromatase inhibitor, is primarily used as a first-line therapy for estrogen receptor-positive breast cancer patients. However, complex physicochemical characteristics of EXE limit its oral bioavailability (<10%) and anti-breast cancer efficacy. The present study aimed to develop a novel nanocarrier system to improve the oral bioavailability and anti-breast cancer efficacy of EXE. In this perspective, EXE-loaded TPGS-based polymer lipid hybrid nanoparticles (EXE-TPGS-PLHNPs) were prepared by the nanoprecipitation method and evaluated for their potential in improving oral bioavailability, safety, and therapeutic efficacy in the animal model. EXE-TPGS-PLHNPs showed significantly higher intestinal permeation in comparison to EXE-PLHNPs (without TPGS) and free EXE. After oral administration, EXE-TPGS-PLHNPs and EXE-PLHNPs revealed 3.58 and 4.69 times higher oral bioavailability in Wistar rats compared to the conventional EXE suspension. The results of the acute toxicity experiment suggested that the developed nanocarrier was safe for oral administration. Furthermore, EXE-TPGS-PLHNPs and EXE-PLHNPs represented much better anti-breast cancer activity in Balb/c mice bearing MCF-7 tumor xenograft with tumor inhibition rate of 72.72% and 61.94% respectively in comparison with the conventional EXE suspension (30.79%) after 21 days of oral chemotherapy. In addition, insignificant changes in the histopathological examination of vital organs and hematological analysis further confirm the safety of the developed PLHNPs. Therefore, the findings of the present investigation advocated that the encapsulation of EXE in PLHNPs can be a promising approach for oral chemotherapy of breast cancer.
Collapse
Affiliation(s)
- Md Rizwanullah
- Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India
| | - Ahmad Perwez
- Genome Biology Lab, Department of Biosciences, Faculty of Natural Sciences, Jamia Millia Islamia, New Delhi 110025, India
| | - Meraj Alam
- Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India
| | - Shahnawaz Ahmad
- Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India
| | - Showkat Rasool Mir
- Department of Pharmacognosy and Phytochemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India
| | - Mohd Moshahid Alam Rizvi
- Genome Biology Lab, Department of Biosciences, Faculty of Natural Sciences, Jamia Millia Islamia, New Delhi 110025, India
| | - Saima Amin
- Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India.
| |
Collapse
|
4
|
Nano-Clays for Cancer Therapy: State-of-the Art and Future Perspectives. J Pers Med 2022; 12:jpm12101736. [PMID: 36294875 PMCID: PMC9605470 DOI: 10.3390/jpm12101736] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2022] [Revised: 10/13/2022] [Accepted: 10/17/2022] [Indexed: 11/17/2022] Open
Abstract
To date, cancer continues to be one of the deadliest diseases. Current therapies are often ineffective, leading to the urgency to develop new therapeutic strategies to improve treatments. Conventional chemotherapeutics are characterized by a reduced therapeutic efficacy, as well as them being responsible for important undesirable side effects linked to their non-specific toxicity. In this context, natural nanomaterials such as clayey mineral nanostructures of various shapes (flat, tubular, spherical and fibrous) with adjustable physico-chemical and morphological characteristics are emerging as systems with extraordinary potential for the delivery of different therapeutic agents to tumor sites. Thanks to their submicron size, high specific surface area, high adsorption capacity, chemical inertia and multilayer organization of 0.7 to 1 nm-thick sheets, they have aroused considerable interest among the scientific community as nano systems that are highly biocompatible in cancer therapy. In oncology, the nano-clays usually studied are halloysite, bentonite, laponite, kaolinite, montmorillonite and sepiolite. These are multilayered minerals that can act as nanocarriers (with a drug load generally between 1 and 10% by weight) for improved stabilization, efficient transport and the sustained and controlled release of a wide variety of anticancer agents. In particular, halloysite, montmorillonite and kaolinite are used to improve the dissolution of therapeutic agents and to delay and/or direct their release. In this review, we will examine and expose to the scientific community the extraordinary potential of nano-clays as unique crystalline systems in the treatment of cancer.
Collapse
|
5
|
Chaturvedi S, Garg A. A comprehensive review on novel delivery approaches for exemestane. J Drug Deliv Sci Technol 2022. [DOI: 10.1016/j.jddst.2022.103655] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
6
|
Peixoto D, Pereira I, Pereira-Silva M, Veiga F, Hamblin MR, Lvov Y, Liu M, Paiva-Santos AC. Emerging role of nanoclays in cancer research, diagnosis, and therapy. Coord Chem Rev 2021. [DOI: 10.1016/j.ccr.2021.213956] [Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
|
7
|
Rizwanullah M, Perwez A, Mir SR, Alam Rizvi MM, Amin S. Exemestane encapsulated polymer-lipid hybrid nanoparticles for improved efficacy against breast cancer: optimization, in vitrocharacterization and cell culture studies. NANOTECHNOLOGY 2021; 32:415101. [PMID: 34198267 DOI: 10.1088/1361-6528/ac1098] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/22/2021] [Accepted: 07/01/2021] [Indexed: 06/13/2023]
Abstract
Polymer-lipid hybrid nanoparticles (PLHNPs) are novel nanoplatforms for the effective delivery of a lipophilic drug in the management of a variety of solid tumors. The present work was designed to develop exemestane (EXE) encapsulated D-alpha-tocopheryl polyethylene glycol succinate (TPGS) based PLHNPs (EXE-TPGS-PLHNPs) for controlled delivery of EXE for breast cancer management. EXE-TPGS-PLHNPs were formulated by single-step nano-precipitation technique and statistically optimized by a 33Box-Behnken design using Design expert®software. The polycaprolactone (PCL;X1), phospholipon 90 G (PL-90G;X2), and surfactant (X3) were selected as independent factors while particles size (PS;Y1), polydispersity index (PDI;Y2), and %entrapment efficiency (%EE;Y3) were chosen as dependent factors. The average PS, PDI, and %EE of the optimized EXE-TPGS-PLHNPs was observed to be 136.37 ± 3.27 nm, 0.110 ± 0.013, and 88.56 ± 2.15% respectively. The physical state of entrapped EXE was further validated by Fourier-transform infrared spectroscopy, differential scanning calorimetry, and powder x-ray diffraction that revealed complete encapsulation of EXE in the hybrid matrix of PLHNPs with no sign of significant interaction between drug and excipients.In vitrorelease study in simulated gastrointestinal fluids revealed initial fast release for 2 h after that controlled release profile up to 24 h of study. Moreover, optimized EXE-TPGS-PLHNPs exhibited excellent stability in gastrointestinal fluids as well as colloidal stability in different storage concentrations. Furthermore, EXE-TPGS-PLHNPs exhibited distinctively higher cellular uptake and time and dose-dependent cytotoxicity against MCF-7 breast tumor cells compared to EXE-PLHNPs without TPGS and free EXE. The obtained results suggested that EXE-TPGS-PLHNPs can be a promising platform for the controlled delivery of EXE for the effective treatment of breast cancer.
Collapse
Affiliation(s)
- Md Rizwanullah
- Formulation Research Lab, Department of Pharmaceutics, School of Pharmaceutical Education and Research (SPER), Jamia Hamdard, New Delhi-110062, India
| | - Ahmad Perwez
- Genome Biology Lab, Department of Biosciences, Faculty of Natural Sciences, Jamia Millia Islamia, New Delhi-110025, India
| | - Showkat Rasool Mir
- Phytopharmaceutical Laboratory, Department of Pharmacognosy and Phytochemistry, School of Pharmaceutical Education and Research (SPER), Jamia Hamdard, New Delhi-110062, India
| | - Mohd Moshahid Alam Rizvi
- Genome Biology Lab, Department of Biosciences, Faculty of Natural Sciences, Jamia Millia Islamia, New Delhi-110025, India
| | - Saima Amin
- Formulation Research Lab, Department of Pharmaceutics, School of Pharmaceutical Education and Research (SPER), Jamia Hamdard, New Delhi-110062, India
| |
Collapse
|
8
|
Yerer MB, Dayan S, Han MI, Sharma A, Tuli HS, Sak K. Nanoformulations of Coumarins and the Hybrid Molecules of Coumarins with Potential Anticancer Effects. Anticancer Agents Med Chem 2021; 20:1797-1816. [PMID: 32156246 DOI: 10.2174/1871520620666200310094646] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2019] [Revised: 11/04/2019] [Accepted: 11/28/2019] [Indexed: 12/13/2022]
Abstract
Coumarins are the secondary metabolites of some plants, fungi, and bacteria. Coumarins and the hybrid molecules of coumarins are the compounds which have been widely studied for their potential anticancer effects. They belong to benzopyrone chemical class, more precisely benzo-α-pyrones, where benzene ring is fused to pyrone ring. In nature, coumarins are found in higher plants like Rutaceae and Umbelliferae and some essential oils like cinnamon bark oil, cassia leaf oil and lavender oil are also rich in coumarins. The six main classes of coumarins are furanocoumarins, dihydrofuranocoumarins, pyrano coumarins, pyrone substituted coumarins, phenylcoumarins and bicoumarins. As well as their wide range of biological activities, coumarins and the hybrid molecules of coumarins are proven to have an important role in anticancer drug development due to the fact that many of its derivatives have shown an anticancer activity on various cell lines. Osthol, imperatorin, esculetin, scopoletin, umbelliprenin, angelicine, bergamottin, limettin, metoxhalen, aurapten and isopimpinellin are some of these coumarins. This review summarizes the anticancer effects of coumarins and their hybrid molecules including the novel pharmaceutical formulations adding further information on the topic for the last ten years and basically focusing on the structureactivity relationship of these compounds in cancer.
Collapse
Affiliation(s)
- Mukerrem Betul Yerer
- Department of Pharmacology, Faculty of Pharmacy, Erciyes University, Kayseri, Turkey.,Drug Application and Research Center, Erciyes University, Kayseri, Turkey
| | - Serkan Dayan
- Drug Application and Research Center, Erciyes University, Kayseri, Turkey
| | - M Ihsan Han
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Erciyes University, Kayseri, Turkey
| | - Ajay Sharma
- Department of Chemistry, Career Point University, Tikker-kharwarian, Hamirpur, Himachal Pradesh 176041, India
| | - Hardeep S Tuli
- Department of Biotechnology, Maharishi Markandeshwar (Deemed to be University), Mullana-Ambala, Haryana-133207, India
| | | |
Collapse
|
9
|
Khatoon N, Chu MQ, Zhou CH. Nanoclay-based drug delivery systems and their therapeutic potentials. J Mater Chem B 2021; 8:7335-7351. [PMID: 32687134 DOI: 10.1039/d0tb01031f] [Citation(s) in RCA: 61] [Impact Index Per Article: 20.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
Safe, therapeutically effective, and patient-compliant drug delivery systems are needed to design novel tools and strategies to combat the deadliest of diseases such as cancer, SARS, H7N9 avian influenza, and dengue infection. The major challenges in drug delivery are cytotoxicity, poor biodistribution, insufficient functionality, ineffective drug incorporation in delivery devices, and subsequent drug release. Clay minerals are a class of nanolayered silicates that have good biocompatibility, high specific surface area, chemical inertness, colloid, and thixotropy, and are attractive practical and potential nanomaterials in medicine. These properties enable the usage of nanoclays as drug carriers for the delivery of antibiotics, antihypertensive drugs, anti-psychotic, and anticancer drugs. The review examines the latest advances in nanoclay-based drug delivery systems and related applications in gene therapy and tissue engineering. Clay minerals, particularly montmorillonite, kaolinite, and halloysite are used to delay and/or target drug release or even improve drug dissolution due to their surface charge. Chemical modification of clay minerals such as intercalation of ions into the interlayer space of clay minerals or surface modification of clay minerals is a strategy to tune the properties of nanoclays for the loading and release of a drug. The modified nanoclay can take up drugs by encapsulation, immobilization, ion exchange reaction, or electrostatic interactions. Controlled drug release from the drug-clay originates from the incorporation and interactions between the drug and inorganic layers, including electrostatic interactions and hydrogen bonding. Montmorillonite has proven non-toxic through hematological, biochemical, and histopathological analyses in rat. Montmorillonite can also act as a potent detoxifier. Halloysite nanotubes can bind synthetic and biological components such as chitosan, gelatin, and alginate innate nanocarriers for the improved loading and controlled release of drugs, proteins, and DNA. The peculiar properties of clay nanoparticles lead to promising applications in drug delivery, gene delivery, tissue engineering, cancer and stem cell isolation, and bioimaging.
Collapse
Affiliation(s)
- Nafeesa Khatoon
- Research Group for Advanced Materials & Sustainable Catalysis (AMSC), State Key Laboratory Breeding Base of Green Chemistry-Synthesis Technology, College of Chemical Engineering, Zhejiang University of Technology, Hangzhou, 310014, China.
| | | | | |
Collapse
|
10
|
|
11
|
Dong J, Cheng Z, Tan S, Zhu Q. Clay nanoparticles as pharmaceutical carriers in drug delivery systems. Expert Opin Drug Deliv 2020; 18:695-714. [PMID: 33301349 DOI: 10.1080/17425247.2021.1862792] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
INTRODUCTION Clay minerals are a class of silicates with chemical inertness, colloid, and thixotropy, which have excellent physicochemical properties, good biocompatibility, low toxicity, and have high application potential in biomedical fields. These inorganic materials have been widely used in pharmaceutical excipients and active substances. In recent years, nanoclay mineral materials have been used as drug vehicles for the delivery of a variety of drugs based on their broad specific surface area, rich porosity, diverse morphology, good adsorption performance, and high ion exchange capacity. AREAS COVERED This review introduces the structures, properties, and applications of various common natural and synthetic nanoclay materials as drug carriers. Natural nanoclays have different morphologies including nanoplates, nanotubes, and nanofibers. Synthetic materials have controllable sizes and flexible structures, where mesoporous silica nanoparticles, laponite, and imogolite are typical ones. These inorganic nanoparticles are often linked to polymers to form multifunctional drug delivery systems for better pharmaceutical performance. EXPERT OPINION The clay nanomaterials have typical properties, including enhanced solubility of insoluble drugs, targeting therapeutic sites, controlled release, and stimulation of responsive drug delivery systems.
Collapse
Affiliation(s)
- Jiani Dong
- Department of Pharmacy, Xiangya School of Pharmaceutical Sciences in Central South University, Changsha, Hunan, China
| | - Zeneng Cheng
- Department of Pharmacy, Xiangya School of Pharmaceutical Sciences in Central South University, Changsha, Hunan, China
| | - Songwen Tan
- Department of Pharmacy, Xiangya School of Pharmaceutical Sciences in Central South University, Changsha, Hunan, China
| | - Qubo Zhu
- Department of Pharmacy, Xiangya School of Pharmaceutical Sciences in Central South University, Changsha, Hunan, China
| |
Collapse
|
12
|
Development and characterization of PLA nanoparticles for pulmonary drug delivery: Co-encapsulation of theophylline and budesonide, a hydrophilic and lipophilic drug. J Drug Deliv Sci Technol 2019. [DOI: 10.1016/j.jddst.2019.101128] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
|
13
|
Jayapal JJ, Dhanaraj S. Exemestane loaded alginate nanoparticles for cancer treatment: Formulation and in vitro evaluation. Int J Biol Macromol 2017; 105:416-421. [DOI: 10.1016/j.ijbiomac.2017.07.064] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2017] [Revised: 05/26/2017] [Accepted: 07/10/2017] [Indexed: 11/29/2022]
|
14
|
Elzoghby AO, El-Lakany SA, Helmy MW, Abu-Serie MM, Elgindy NA. Shell-crosslinked zein nanocapsules for oral codelivery of exemestane and resveratrol in breast cancer therapy. Nanomedicine (Lond) 2017; 12:2785-2805. [DOI: 10.2217/nnm-2017-0247] [Citation(s) in RCA: 62] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Aim: Oral administration of exemestane (EXM) and resveratrol (RES) for breast cancer therapy has been limited by their poor solubility and low permeability. Methods: In this study, these issues were tackled using zein nanocapsules (ZNCs) for oral EXM/RES codelivery combining drug solubilization within oily core and resistance to digestion via hydrophobic protein shell. Furthermore, higher oral stability and sustained release could be enabled by glutaraldehyde crosslinking of zein shell. Results & conclusion: EXM/RES-ZNCs showed enhanced cytotoxicity against MCF-7 and 4T1 breast cancer cells compared with free drug combination with higher selectivity to cancer cells rather than normal fibroblasts. In vivo, crosslinked EXM/RES-ZNCs markedly reduced the percentage increase of Ehrlich ascites mammary tumor volume in mice by 2.4-fold compared with free drug combination.
Collapse
Affiliation(s)
- Ahmed O Elzoghby
- Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt
- Department of Industrial Pharmacy, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt
| | - Sarah A El-Lakany
- Department of Industrial Pharmacy, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt
| | - Maged W Helmy
- Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt
- Department of Pharmacology & Toxicology, Faculty of Pharmacy, Damanhour University, Damanhour, Egypt
| | - Marwa M Abu-Serie
- Medical Biotechnology Department, Genetic Engineering & Biotechnology Research Institute, City of Scientific Research & Technological Applications, New-Borg El-Arab City, Alexandria 21934, Egypt
| | - Nazik A Elgindy
- Department of Industrial Pharmacy, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt
| |
Collapse
|
15
|
Wu L, Zhang Z, Gao H, Li Y, Hou L, Yao H, Wu S, Liu J, Wang L, Zhai Y, Ou H, Lin M, Wu X, Liu J, Lang G, Xin Q, Wu G, Luo L, Liu P, Shentu J, Wu N, Sheng J, Qiu Y, Chen W, Li L. Open-label phase I clinical trial of Ad5-EBOV in Africans in China. Hum Vaccin Immunother 2017; 13. [PMID: 28708962 DOI: 10.1002/smll.201701815] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2017] [Revised: 07/31/2017] [Indexed: 04/16/2023] Open
Abstract
BACKGROUND To determine the safety and immunogenicity of a novel recombinant adenovirus type 5 vector based Ebola virus disease vaccine (Ad5-EBOV) in Africans in China. METHODS A phase 1, dose-escalation, open-label trial was conducted. 61 healthy Africans were sequentially enrolled, with 31 participants receiving one shot intramuscular injection and 30 participants receiving a double-shot regimen. Primary and secondary end points related to safety and immunogenicity were assessed within 28 d after vaccination. This study was registered with ClinicalTrials.gov (NCT02401373). RESULTS Ad5-EBOV is well tolerated and no adverse reaction of grade 3 or above was observed. 53 (86.89%) participants reported at least one adverse reaction within 28 d of vaccination. The most common reaction was fever and the mild pain at injection site, and there were no significant difference between these 2 groups. Ebola glycoprotein-specific antibodies appeared in all 61 participants and antibodies titers peaked after 28 d of vaccination. The geometric mean titres (GMTs) were similar between these 2 groups (1919.01 vs 1684.70 P = 0.5562). The glycoprotein-specific T-cell responses rapidly peaked after 14 d of vaccination and then decreased, however, the percentage of subjects with responses were much higher in the high-dose group (60.00% vs 9.68%, P = 0.0014). Pre-existing Ad5 neutralizing antibodies could significantly dampen the specific humoral immune response and cellular response to the vaccine. CONCLUSION The application of Ad5-EBOV demonstrated safe in Africans in China and a specific GP antibody and T-cell response could occur 14 d after the first immunization. This acceptable safety profile provides a reliable basis to proceed with trials in Africa.
Collapse
MESH Headings
- Adult
- Africa/epidemiology
- Antibodies, Neutralizing/blood
- Antibodies, Viral/blood
- China
- Ebola Vaccines/administration & dosage
- Ebola Vaccines/adverse effects
- Ebola Vaccines/immunology
- Ebolavirus/immunology
- Female
- Fever/ethnology
- Healthy Volunteers
- Hemorrhagic Fever, Ebola/epidemiology
- Hemorrhagic Fever, Ebola/ethnology
- Hemorrhagic Fever, Ebola/immunology
- Hemorrhagic Fever, Ebola/prevention & control
- Humans
- Immunity, Cellular
- Immunity, Humoral
- Immunogenicity, Vaccine
- Injections, Intramuscular
- Male
- Membrane Glycoproteins/immunology
- Middle Aged
- T-Lymphocytes/immunology
- Vaccination
- Young Adult
Collapse
Affiliation(s)
- Lihua Wu
- a The First Affiliated Hospital, College of Medicine, Zhejiang University , Xiacheng District, Hangzhou , Zhejiang , China
- b The Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases , Xiacheng District, Hangzhou , Zhejiang , China
| | - Zhe Zhang
- c Beijing Institute of Biotechnology , Haidian District, Beijing , China
| | - Hainv Gao
- b The Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases , Xiacheng District, Hangzhou , Zhejiang , China
- d Zhejiang University International Hospital , Xiacheng District, Hangzhou , Zhejiang , China
| | - Yuhua Li
- e National Institutes for Food and Drug Control , Chongwen District, Beijing , China
| | - Lihua Hou
- c Beijing Institute of Biotechnology , Haidian District, Beijing , China
| | - Hangping Yao
- a The First Affiliated Hospital, College of Medicine, Zhejiang University , Xiacheng District, Hangzhou , Zhejiang , China
- b The Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases , Xiacheng District, Hangzhou , Zhejiang , China
| | - Shipo Wu
- c Beijing Institute of Biotechnology , Haidian District, Beijing , China
| | - Jian Liu
- a The First Affiliated Hospital, College of Medicine, Zhejiang University , Xiacheng District, Hangzhou , Zhejiang , China
- b The Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases , Xiacheng District, Hangzhou , Zhejiang , China
| | - Ling Wang
- e National Institutes for Food and Drug Control , Chongwen District, Beijing , China
| | - You Zhai
- a The First Affiliated Hospital, College of Medicine, Zhejiang University , Xiacheng District, Hangzhou , Zhejiang , China
- b The Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases , Xiacheng District, Hangzhou , Zhejiang , China
| | - Huilin Ou
- a The First Affiliated Hospital, College of Medicine, Zhejiang University , Xiacheng District, Hangzhou , Zhejiang , China
- b The Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases , Xiacheng District, Hangzhou , Zhejiang , China
| | - Meihua Lin
- a The First Affiliated Hospital, College of Medicine, Zhejiang University , Xiacheng District, Hangzhou , Zhejiang , China
- b The Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases , Xiacheng District, Hangzhou , Zhejiang , China
| | - Xiaoxin Wu
- b The Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases , Xiacheng District, Hangzhou , Zhejiang , China
- d Zhejiang University International Hospital , Xiacheng District, Hangzhou , Zhejiang , China
| | - Jingjing Liu
- e National Institutes for Food and Drug Control , Chongwen District, Beijing , China
| | - Guanjing Lang
- a The First Affiliated Hospital, College of Medicine, Zhejiang University , Xiacheng District, Hangzhou , Zhejiang , China
- b The Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases , Xiacheng District, Hangzhou , Zhejiang , China
| | - Qian Xin
- f The General Hospital of People's Liberation Army , Beijing , China
| | - Guolan Wu
- a The First Affiliated Hospital, College of Medicine, Zhejiang University , Xiacheng District, Hangzhou , Zhejiang , China
- b The Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases , Xiacheng District, Hangzhou , Zhejiang , China
| | - Li Luo
- g Department of Epidemiology and Biostatistics , School of Public Health, Southeast University , Nanjing , Jiangsu , China
| | - Pei Liu
- g Department of Epidemiology and Biostatistics , School of Public Health, Southeast University , Nanjing , Jiangsu , China
| | - Jianzhong Shentu
- a The First Affiliated Hospital, College of Medicine, Zhejiang University , Xiacheng District, Hangzhou , Zhejiang , China
- b The Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases , Xiacheng District, Hangzhou , Zhejiang , China
| | - Nanping Wu
- a The First Affiliated Hospital, College of Medicine, Zhejiang University , Xiacheng District, Hangzhou , Zhejiang , China
- b The Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases , Xiacheng District, Hangzhou , Zhejiang , China
| | - Jifang Sheng
- a The First Affiliated Hospital, College of Medicine, Zhejiang University , Xiacheng District, Hangzhou , Zhejiang , China
- b The Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases , Xiacheng District, Hangzhou , Zhejiang , China
| | - Yunqing Qiu
- a The First Affiliated Hospital, College of Medicine, Zhejiang University , Xiacheng District, Hangzhou , Zhejiang , China
- b The Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases , Xiacheng District, Hangzhou , Zhejiang , China
| | - Wei Chen
- c Beijing Institute of Biotechnology , Haidian District, Beijing , China
| | - Lanjuan Li
- a The First Affiliated Hospital, College of Medicine, Zhejiang University , Xiacheng District, Hangzhou , Zhejiang , China
- b The Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases , Xiacheng District, Hangzhou , Zhejiang , China
- d Zhejiang University International Hospital , Xiacheng District, Hangzhou , Zhejiang , China
| |
Collapse
|
16
|
Bugde P, Biswas R, Merien F, Lu J, Liu DX, Chen M, Zhou S, Li Y. The therapeutic potential of targeting ABC transporters to combat multi-drug resistance. Expert Opin Ther Targets 2017; 21:511-530. [DOI: 10.1080/14728222.2017.1310841] [Citation(s) in RCA: 73] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Affiliation(s)
- Piyush Bugde
- School of Science, Auckland University of Technology, Auckland, New Zealand
| | - Riya Biswas
- School of Science, Auckland University of Technology, Auckland, New Zealand
| | - Fabrice Merien
- School of Science, Auckland University of Technology, Auckland, New Zealand
- School of Science, AUT Roche Diagnostic Laboratory, Auckland University of Technology, Auckland, New Zealand
| | - Jun Lu
- School of Science, Auckland University of Technology, Auckland, New Zealand
- School of Interprofessional Health Studies, Auckland University of Technology, Auckland, New Zealand
| | - Dong-Xu Liu
- School of Science, Auckland University of Technology, Auckland, New Zealand
| | - Mingwei Chen
- Department of Respiratory Medicine, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
| | - Shufeng Zhou
- Department of Biotechnology and Bioengineering, College of Chemical Engineering, Huaqiao University, Xiamen, China
| | - Yan Li
- School of Science, Auckland University of Technology, Auckland, New Zealand
- School of Interprofessional Health Studies, Auckland University of Technology, Auckland, New Zealand
| |
Collapse
|
17
|
Sobral AF, Amaral C, Correia-da-Silva G, Teixeira N. Unravelling exemestane: From biology to clinical prospects. J Steroid Biochem Mol Biol 2016; 163:1-11. [PMID: 26992705 DOI: 10.1016/j.jsbmb.2016.03.019] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/02/2015] [Revised: 02/29/2016] [Accepted: 03/13/2016] [Indexed: 11/28/2022]
Abstract
Aromatase inhibitors (AIs) are anti-tumor agents used in clinic to treat hormone-dependent breast cancer. AIs block estrogens biosynthesis by inhibiting the enzyme aromatase, preventing tumor progression. Exemestane, a third-generation steroidal AI, belongs to this class of drugs and is currently used in clinic to treat postmenopausal women, due to its high efficacy and good tolerability. Here, its pharmacological and biological aspects as well as its clinical applications and comparison to other endocrine therapeutic agents, are reviewed. It is also focused the benefits and risks of exemestane, drawbacks to be overcome and aspects to be explored.
Collapse
Affiliation(s)
- Ana Filipa Sobral
- Faculty of Science and Technology, University of Coimbra, Calçada Martim de Freitas 3000-456 Coimbra, Portugal; UCIBIO-REQUIMTE, Laboratory of Biochemistry, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, no 228, 4050-313 Porto, Portugal
| | - Cristina Amaral
- UCIBIO-REQUIMTE, Laboratory of Biochemistry, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, no 228, 4050-313 Porto, Portugal.
| | - Georgina Correia-da-Silva
- UCIBIO-REQUIMTE, Laboratory of Biochemistry, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, no 228, 4050-313 Porto, Portugal
| | - Natércia Teixeira
- UCIBIO-REQUIMTE, Laboratory of Biochemistry, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, no 228, 4050-313 Porto, Portugal.
| |
Collapse
|
18
|
Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies. Drug Resist Updat 2016; 27:14-29. [DOI: 10.1016/j.drup.2016.05.001] [Citation(s) in RCA: 463] [Impact Index Per Article: 57.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2015] [Revised: 04/24/2016] [Accepted: 05/06/2016] [Indexed: 12/15/2022]
|
19
|
Sun D, Xue A, Zhang B, Xue X, Zhang J, Liu W. Enhanced oral bioavailability of acetylpuerarin by poly(lactide-co-glycolide) nanoparticles optimized using uniform design combined with response surface methodology. DRUG DESIGN DEVELOPMENT AND THERAPY 2016; 10:2029-39. [PMID: 27382256 PMCID: PMC4922808 DOI: 10.2147/dddt.s108185] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Acetylpuerarin (AP), an acetylated derivative of puerarin, shows brain-protective effects in animals. However, AP has low oral bioavailability because of its poor water solubility. The objective of this study was to design and develop poly(lactide-co-glycolide) (PLGA) nanoparticles (NPs) to enhance the oral bioavailability of AP. The NPs were prepared using a solvent diffusion method optimized via uniform design (UD) combined with response surface methodology (RSM) and characterized by their morphology, particle size, zeta (ζ)-potential, encapsulation efficiency (EE), drug loading (DL), and in vitro drug release. A pharmacokinetic study was conducted in Wistar rats administered a single oral dose of 30 mg/kg AP. The optimized NPs were spherical and uniform in shape, with an average particle size of 145.0 nm, a polydispersity index (PI) of 0.153, and a ζ-potential of −14.81 mV. The release of AP from the PLGA NPs showed an initial burst release followed by a sustained release, following Higuchi’s model. The EE and DL determined in the experiments were 90.51% and 17.07%, respectively. The area under the plasma concentration-time curve (AUC0−∞) of AP-PLGA-NPs was 6,175.66±350.31 h ng/mL, which was 2.75 times greater than that obtained from an AP suspension. This study showed that PLGA NPs can significantly enhance the oral bioavailability of AP.
Collapse
Affiliation(s)
- Deqing Sun
- Department of Pharmacy, the Second Hospital of Shandong University, Jinan, People's Republic of China; School of Pharmaceutical Sciences, Shandong University, Jinan, People's Republic of China
| | - Aiying Xue
- Department of Cardiology, the Second Hospital of Shandong University, Jinan, People's Republic of China
| | - Bin Zhang
- Department of Pharmacy, the Second Hospital of Shandong University, Jinan, People's Republic of China
| | - Xia Xue
- Department of Pharmacy, the Second Hospital of Shandong University, Jinan, People's Republic of China
| | - Jie Zhang
- Department of Pharmacy, the Second Hospital of Shandong University, Jinan, People's Republic of China
| | - Wenjie Liu
- Department of Pharmacy, the Second Hospital of Shandong University, Jinan, People's Republic of China
| |
Collapse
|
20
|
El-Lakany SA, Elzoghby AO, Elgindy NA, Hamdy DA. HPLC Methods for Quantitation of Exemestane-Luteolin and Exemestane-Resveratrol Mixtures in Nanoformulations. J Chromatogr Sci 2016; 54:1282-9. [PMID: 27130876 DOI: 10.1093/chromsci/bmw063] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2015] [Indexed: 12/12/2022]
Abstract
Two HPLC-DAD assays for the simultaneous quantitation of exemestane (EXE) and resveratrol (RES)-Mix 1-and EXE and luteolin (LUT)-Mix 2-in novel breast cancer therapy nanoformulations were developed. Calibration curves 15-30 µg/mL and samples were injected through an Inertsil ODS-3 (250 × 4.6 mm, 5 µm) column. The gradient elution for Mix 1 was methanol : 0.05% (v/v) acetic acid in water (60 : 40 to 80 : 20, linear over 2 min), and for Mix 2, it was methanol : water (60 : 40 for 4 min, then ramped linearly to 90 : 10, over 12 min) pumped at 1.5 mL/min for 4 min, then 1 mL/min till the end of run. EXE, RES, LUT and flutamide (internal standard (IS)) were measured at 246, 307, 350 and 300 nm, respectively. For Mix 1, RES, EXE and IS eluted at 3.5, 6.8 and 7.4 min, respectively, while for Mix 2, LUT, EXE and IS eluted at 7.5, 11.4 and 12.7 min, respectively. The mean r(2) for the standard curves was ≥0.99, and percentage coefficient of variation and % error of the mean were <2. Both assays successfully quantitated Mix 1 and Mix 2 in their nanoformulations. The two developed assays were sensitive and selective for the analysis of EXE-LUT and EXE-RES mixtures in nanoformulations according to International Conference on Harmonization guidelines.
Collapse
Affiliation(s)
- Sarah A El-Lakany
- Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt Department of Industrial Pharmacy, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt
| | - Ahmed O Elzoghby
- Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt Department of Industrial Pharmacy, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt
| | - Nazik A Elgindy
- Department of Industrial Pharmacy, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt
| | - Dalia A Hamdy
- Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Alexandria University, 1 El Khartoum Square, PO Box 21521, Alexandria 21521, Egypt
| |
Collapse
|
21
|
Zhong J, Zhang H, Yan J, Gong X. Effect of nanofiber orientation of electrospun nanofibrous scaffolds on cell growth and elastin expression of muscle cells. Colloids Surf B Biointerfaces 2015; 136:772-8. [PMID: 26520049 DOI: 10.1016/j.colsurfb.2015.10.017] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2015] [Revised: 09/28/2015] [Accepted: 10/11/2015] [Indexed: 01/09/2023]
Abstract
Tissue regeneration after smooth muscle tissue injury is a pivotal issue in tissue engineering. Good artificial scaffolds to continuously form long thin spindle-shaped smooth muscle cells in the damaged muscle tissues are important for tissue regeneration. In this work, poly(lactide-co-glycolide) (PLGA) and poly(ϵ-caprolactone) (PCL) were used to fabricate aligned or random electrospun nanofibrous scaffolds (ENSs) by using electrospinning technique. The cell growth and elastin expression of human vascular smooth muscle cells (HVSMCs) on these membranes were analyzed. Smooth PLGA/PCL film was used as control. The experimental results showed that the aligned ENS could maintain cell shapes of HVSMCs during the culture process. During the HVSMCs proliferation process, elastin expression firstly increase due to cell proliferation, and then decrease due to elastin degradation by elastase secreted by the cells. All these results suggest that aligned PLGA/PCL ENS can be a promising candidate for cell regeneration after smooth muscle tissue injury.
Collapse
Affiliation(s)
- Jian Zhong
- College of Food Science & Technology, Shanghai Ocean University, Shanghai 201306, People's Republic of China.
| | - Huan Zhang
- Iowa State University, Ames Laboratory, Ames, IA 50010, USA
| | - Juan Yan
- College of Food Science & Technology, Shanghai Ocean University, Shanghai 201306, People's Republic of China
| | - Xiao Gong
- Department of Chemical & Petroleum Engineering, Swanson School of Engineering, University of Pittsburgh, Pittsburgh, PA 15261, USA
| |
Collapse
|